Adalta Ltd (1AD) - Total Liabilities

Latest as of June 2025: AU$2.74 Million AUD ≈ $1.94 Million USD

Based on the latest financial reports, Adalta Ltd (1AD) has total liabilities worth AU$2.74 Million AUD (≈ $1.94 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 1AD cash flow metrics to assess how effectively this company generates cash.

Adalta Ltd - Total Liabilities Trend (2012–2025)

This chart illustrates how Adalta Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Adalta Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Adalta Ltd Competitors by Total Liabilities

The table below lists competitors of Adalta Ltd ranked by their total liabilities.

Company Country Total Liabilities
Intelligent Bio Solutions Inc.
NASDAQ:INBS
USA $6.61 Million
Armada Berjaya Trans Tbk PT
JK:JAYA
Indonesia Rp150.47 Billion
Fobi AI Inc
V:FOBI
Canada CA$2.62 Million
Xylo Technologies Ltd.
NASDAQ:XYLO
USA $19.96 Million
ICDS Limited
NSE:ICDSLTD
India Rs30.86 Million
Victrex plc
LSE:VCT
UK GBX135.70 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Adalta Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 1AD market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -4.58 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Adalta Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Adalta Ltd (2012–2025)

The table below shows the annual total liabilities of Adalta Ltd from 2012 to 2025.

Year Total Liabilities Change
2025-06-30 AU$2.74 Million
≈ $1.94 Million
-22.66%
2024-06-30 AU$3.54 Million
≈ $2.51 Million
-39.16%
2023-06-30 AU$5.82 Million
≈ $4.12 Million
+10.50%
2022-06-30 AU$5.27 Million
≈ $3.73 Million
+97.90%
2021-06-30 AU$2.66 Million
≈ $1.88 Million
-16.92%
2020-06-30 AU$3.21 Million
≈ $2.27 Million
+76.22%
2019-06-30 AU$1.82 Million
≈ $1.29 Million
+396.54%
2018-06-30 AU$366.32K
≈ $259.19K
+6.33%
2017-06-30 AU$344.51K
≈ $243.76K
+201.86%
2016-06-30 AU$114.13K
≈ $80.75K
-56.30%
2015-06-30 AU$261.18K
≈ $184.80K
-8.98%
2014-06-30 AU$286.95K
≈ $203.03K
-11.39%
2013-06-30 AU$323.83K
≈ $229.13K
+81.93%
2012-06-30 AU$178.00K
≈ $125.95K
--

About Adalta Ltd

AU:1AD Australia Biotechnology
Market Cap
$6.50 Million
AU$9.18 Million AUD
Market Cap Rank
#27838 Global
#1482 in Australia
Share Price
AU$0.00
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.37
About

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more